RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Clinical trials for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug CLN-049 aims to fight Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called CLN-049 in about 60 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. CLN-049 is designed to help the body's immune cells attack cancer cells. The main goals …
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Can lab tests guide better AML treatment choices?
Knowledge-focused Recruiting nowThis study explores whether combining a drug sensitivity test with detailed genetic profiling can help doctors recommend the best treatment for each patient with relapsed or refractory acute myeloid leukemia (AML). Researchers will take extra blood or bone marrow samples from 18 …
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC